EXELExelixis Inc.

Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in clinical practice. Exelixis also advances a broader pipeline of small-molecule and biotherapeutic candidates aimed at expanding treatment options in solid tumors and other oncology settings. In addition to internal drug development, the company works through collaborations to support research, development, and commercialization activities. Based in Alameda, California, Exelixis plays a significant role in the cancer treatment market by combining approved products with an active development pipeline focused on targeted oncology medicines.